Clinical implications of serum Anti-P53 antibodies for patients with gastric carcinoma

Abstract EN

Mutations of P53 can lead to the production of jnti-P53 antibodies in sera of cancer patients.

We use a highly specific enzyme-Iitiked immunosorbent assay (ELISA) to determine the presence of serum anti-P53 antibodies in 30 patients with gastric carcinoma.

Anti-pS3 antibodies were detected in 20 % (6 of 30) of these patients with gastric carcinoma.

Among those who were positive for anti-P53 antibodies, female patients were predominant, the depth of invasion was greater, and liver metastasis was present, as compared with those who were negative for anti-P53 antibodies.

Alpha-feto protein (AFP), a tumor marker specific for cancer liver, was high in (3 of 30) 10 % of these patients, also carcino embryonic antigen (CEA), a tumor marker of colorectal cancer, was high only in one case (I of 30) 3 3K> of these patients It is concluded that scrum assay of anii-P53 antibodies is a rapid and readily facilitated test for predicting tumor advancement, both depth of invasion, and liver metastasis.

In addition, it will show a poorer prognosis for surgically treated patients with gastric carcinoma and also better than tumor markers ; AFP and CEA, in predicting metastasis of gastric carcinoma.